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Abstract
HIV-1 can disseminate between susceptible cells by two mechanisms: cell-free infection following fluid-phase dif-
fusion of virions and by highly-efficient direct cell-to-cell transmission at immune cell contacts. The contribution
of this hybrid spreading mechanism, which is also a characteristic of some important computer worm outbreaks, to
HIV-1 progression in vivo remains unknown. Here we present a new mathematical model that explicitly incorporates
the ability of HIV-1 to use hybrid spreading mechanisms and evaluate the consequences for HIV-1 pathogenenesis.
The model captures the major phases of the HIV-1 infection course of a cohort of treatment naive patients and also
accurately predicts the results of the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial. Using
this model we find that hybrid spreading is critical to seed and establish infection, and that cell-to-cell spread and
increased CD4+ T cell activation are important for HIV-1 progression. Notably, the model predicts that cell-to-cell
spread becomes increasingly effective as infection progresses and thus may present a considerable treatment barrier.
Deriving predictions of various treatments’ influence on HIV-1 progression highlights the importance of earlier in-
tervention and suggests that treatments effectively targeting cell-to-cell HIV-1 spread can delay progression to AIDS.
This study suggests that hybrid spreading is a fundamental feature of HIV infection, and provides the mathematical
framework incorporating this feature with which to evaluate future therapeutic strategies.
Author Summary
The ability to spread using more than once mechanism, named hybrid spreading, is a ubiquitous feature of many real
world epidemics including HIV and Hepatitis C virus infection in vivo, and computer worms spreading on the Internet.
Hybrid spreading of HIV is well documented experimentally but its importance to HIV progression has been unclear.
In this paper, we introduce a mathematical model of HIV dynamics that explicitly incorporates hybrid spreading. The
model output shows excellent agreement to two sets of clinical data from a treatment naive cohort and from the Short
Pulse Anti-Retroviral Therapy at Seroconversion trial. The model demonstrates that hybrid spreading is an essential
feature of HIV progression, a result which has significant implications for future therapeutic strategies against HIV.
Introduction
The course of HIV-1 infection is typified by three phases; acute infection characterized by a rapid viraemia peak (3-6
weeks post-infection) followed by a rapid fall in virus levels, a stable chronic phase of variable length characterized
by low level viraemia and slowly declining CD4+ T cell numbers, and a final stage (Acquired Immune Deficiency
Syndrome, AIDS) characterized by multiple opportunistic infections and a rapid fall in CD4+ T cell count. The cellular
and viral changes which drive each phase of this complex infection have been the subject of intense debate, in which
mathematical models have played an important role in delineating HIV-1 pathogenesis and informing antiretroviral
therapy [1, 2, 3]. The rich literature appertaining to mathematical modeling of intra host HIV dynamics has been
reviewed several times recently [1, 4, 5, 6]. Recent studies incorporate sophisticated models of immune selection
[7, 8], as well as the formation of a latent reservoir of quiescent infected cells [9, 10]. However the interplay of cell-to-
1
ar
X
iv
:1
50
3.
08
99
2v
1 
 [q
-b
io.
PE
]  
31
 M
ar 
20
15
cell spread and increased CD4+ T cell activation, that are likely to have profound influences on the progression of the
disease have been hitherto little studied. Here we have addressed this and developed a unified model that can explain
the complex progress of the infection in all its phases and its variable timescale. Such a unified model is important not
only to understand the HIV-1 infection dynamics, but also to estimate the long term effects of therapeutic strategies on
HIV-1 progression. In this paper, unless otherwise stated, “T cells” refers to CD4+ T cells.
HIV-1 predominantly replicates in CD4+ T cells in vivo, and is now known to spread between T cells by two parallel
routes. According to the classical model of HIV-1 spread, virus particles bud from an infected T cell, enter the
blood/extracellular fluid and then infect another T cell following a chance encounter (termed cell-free spread). Because
diffusion of virus particles is much faster than cell migration, and there is extensive flow of blood and fluid, this mode
of spreading can be characterized by a well mixed epidemic spreading model. In this scenario, the probability of
infection for a particular cell will be proportional to the concentration of extracellular infectious virus. However,
HIV-1 can also disseminate by direct transmission from one cell to another by a process of cell-to-cell spread. Two
pathways of cell-to-cell transmission have been reported. Firstly, an infected T cell can transmit virus directly to a
target T cell via a virological synapse [11, 12, 13]. Secondly, an antigen presenting cell (APC) can also transmit
HIV-1 to T cells by a process that either involves productive infection (in the case of macrophages) or capture and
transfer of virions in trans (in the case of dendritic cells) [11]. Whichever pathway is used, infection by cell-to-cell
transfer is reported to be much more efficient than cell-free virus spread [14, 15, 16]. A number of factors contribute
to this increased efficiency, including polarised virus budding towards the site of cell-to-cell contact, close apposition
of cells which minimizes fluid-phase diffusion of virions, and clustering of HIV-1 entry receptors on the target cell to
the contact zone [11, 12]. Cell-to-cell spread is thought to be particularly important in lymphoid tissues where CD4+
T lymphocytes are densely packed and likely to frequently interact. Indeed, intravital imaging studies have supported
the concept of the HIV-1 virological synapse in vivo [17, 18].
Hybrid spreading is in fact a feature of other viral infections [19], but is also shared in other “epidemic” scenarios
such as spread of computer worms [20, 21], or of mobile phone viruses [22]. The mathematical analysis of hybrid
spreading has received significant previous attention [22, 23, 24, 25]. However, the importance of hybrid spread to
HIV-1 dissemination and disease progression, has not been explored from a mathematical point of view.
In this paper we develop a new mathematical model which incorporates the basic principles of previous host-centric
models including a virus-dependent immune response [8], viral latency and a progressive increase in cell activation
[26, 27]. Notably, the model additionally includes explicit terms for the two modes of virus spread, parametrised from
experimental observation. The model faithfully replicates the overall three phase course of HIV-1 infection . The
model predictions are consistent with both a set of longitudinal data (viral load and CD4+ T cell count) from a cohort
of treatment naive HIV-1 infected patients and the results of the Short Pulse Anti-Retroviral Therapy at Seroconversion
(SPARTAC) trial that aims to evaluate how the short-course antiretroviral therapy (ART) delays HIV progression [28].
The results of our study reveal the importance of two modes of HIV-1 spread, highlight the close link between cell-
to-cell spread and cell activation in driving the progression of HIV-1 infection to AIDS and support early therapeutic
intervention (i.e. “test-and-treat” initiatives) to delay disease progression in infected individuals. Since cell-to-cell
spread is likely to present a considerable barrier to HIV-1 eradication, our data suggest that efforts to target this mode
of viral spread whilst simultaneously manipulating CD4+ T cell activation may be a fruitful strategy to help control
virus infection and halt progression to AIDS.
Results
The HIV-1 model
We here introduce a model of HIV-1 infection as depicted in Figure 1A. We consider four distinct CD4+ T cell states:
activated, uninfected susceptible (S) cells; activated and productively infected (I) cells ; quiescent, uninfected (Q)
cells; and quiescent latently (L) infected cells. The total CD4+ cell density (N) changes with time and is given by
the sum of these four terms, i.e. N(t) = Q(t) + S(t) + I(t) + L(t). The model can be described by an Ordinary
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Differential Equation (ODE) system (equation (1)) and is illustrated in Figure 1A.
dQ
dt
= −γQ+ rSS − aNM
N
Q+ b
dS
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(1)
The density variables (Q, S, I, L, V) and parameters are defined in Table 1. The densities are measured as numbers of
cells or virions in a µl of blood/extracellular fluid. We set a density variable to zero when it drops to below 10−12/µl,
accounting for the fact that when density of cells or virions drops to such low level, there is a high probability that it
would die out (density becomes zero). The default value of parameters, shown in Table 1, are taken from the literature
or estimated from clinical and experimentally observed data. The killing coefficient κ equals to its value in Table 1
when t ≥ D; otherwise κ = 0 when t < D.
Table 1: Variables and parameters of our model
Variables Initial value Unit
Q Density of quiescent CD4+ T cells a Q0 = 708 cells/µl
S Density of susceptible CD4+ T cells a S0 = 17 cells/µl
I Density of infected CD4+ T cells I0 = 0 cells/µl
L Density of latent CD4+ T cells L0 = 0 cells/µl
N Density of all CD4+ T cells N0 = 725 cells/µl
V Density of free HIV-1 virus V0 = 10−6 virions/µl
Parameters Default value Unit Reference
γ Death rate of quiescent and latent cells 0.001 /day [29]
γS Death rate of susceptible cells 0.0625 /day [30]
γI Death rate of infected cells 0.5 /day [29]
b Production rate of new quiescent cells b 0.17 cells/µl/day [31]
rS Resting rate of susceptible cells 0.5 /day
rI Resting rate of infected cells 0.0001 /day
a Cell activation coefficient 0.01 /day
p Cell proliferation coefficient 1 /day [29]
NM Cell threshold density c 800 cells/µl
g Virus release rate from an infected cell 100 virions/cell/day [29]
γV Virus death rate 3 /day [31, 29]
c Cell contact rate d 330 /day [14, 32, 33]
θ Cell synapse rate e 0.56 [12, 14, 32, 34]
β1 Cell-to-cell infection rate f 0.19 [15, 33, 35, 36]
β2 Cell-free infection rate 0.00135 µl/virions/day [29]
D Immune response delay g 30 days [37]
κ Killing coefficient (when t > D) h 1.5 /day
a Q0 and S0 are chosen to maintain a stable density of CD4+ T cells (N0 = 725 cell/µl) in the absence of an infection; b
Production from sources including thymus; c Beyond this threshold CD4+ T cell proliferation stops; d The average number of
effective contacts between two CD4+ T cells. Cells contact each other frequently, but only a proportion (20 − 25%) of these
random contacts are sufficiently stable and “effective” for a synapse to be formed at rate θ; e The average probability to form a
virological synapse when two cells have an effective contact; f The average probability that a susceptible cell is infected when
it forms a synapse with an infected cell; g Between the initial infection and the onset of cellular immune response, including the
period before symptoms begin; h κ = 0 when t < D.
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Figure 1: The HIV-1 model reproduces the full course of HIV-1 infection. (A) Diagrammatic representation of the
model described by equation (1). (B) Numerical solutions of the model, plotting N , the density of all CD4+ T cells
(y axis on the left) and V , the density of free virions (y axis on the right in log scale) as a function of time (in days or
weeks), respectively. The initial infection starts on day 0 and the cellular immune response starts on day 30. Parameter
values are in Table 1.(C) The density of quiescent, susceptible, latent and infected CD4+ T cells, and the density of
free virions as function of time (in days).
The production rate of new quiescent T cells from sources, such as thymus, within the human body is represented
by b. Quiescent T cells are activated and become susceptible at a variable activation rate a(NM/N), where a is the
activation coefficient and NM is the density of T cells at which proliferation stops. The activation rate a(NM/N)
increases as the total T cell density (N ) falls (caused by the HIV-1 progression). The detailed mechanism of how the
activation rate increases with the progression of HIV-1 is still unclear, and may include increased rates of co-infections,
danger signals from dying T cells or homeostatic regulatory loops. This term, a(NM/N), here is an approximation,
which encompasses the combined effects of all these different mechanisms. Quiescent T cells die at a rate of γ.
Susceptible T cells turn into quiescent T cells at a rate r. They proliferate at a variable rate p(1 − N/NM ), where p
is the proliferation coefficient, N is the total T cell density, and NM is the T cell density at which proliferation stops.
This variable proliferation rate is a reasonable approximation [29] to the real T cell proliferation process, based on
evidence [2] that T cell proliferation rate is density-dependent and would slow as the T cell density becomes high.
Susceptible T cells die at a rate γS .
Susceptible T cells become infected through both cell-to-cell and cell-free infection. For cell-free infection, the newly
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infected susceptible T cells per unit period of time are β2SV , where β2 is the infection rate of susceptible T cells by free
virus. For cell-to-cell infection, we consider that the T cells are randomly moving, i.e. a T cell has an equal chance of
contacting any other T cells. Let c represent the number of effective contacts each T cell makes in a unit period of time.
Then the number of contacts made by all infected T cells per unit period of time is cI . Among those contacts, S/N
are contacts with a susceptible T cell that could potentially end up with a new infection. Let θ represent the Synapse
rate: the average probability that two T cells form a virological synapse once they have made an effective contact.
Then the newly infected susceptible T cells through cell-to-cell infection per unit time period can be represented as
cI(S/N)θβ1, where β1 is the cell-to-cell infection rate when an infected T cell and a susceptible T cell form a synapse.
In reality, cell-to-cell transfer occurs locally involving only the infected cell and its immediate neighbours. The model
abstracts this process by averaging infection over all cells. In practice, local effects will only distort this average when
target cells in the vicinity of an infected cell become limiting. This limit seems unlikely to be reached except very late
in infection, given that infected cells continue to migrate, albeit at a slower rate (personal observations and [17]), and
uninfected target cells continue to migrate into the vicinity of an infected cell. More complex spatial models will be
required, however, to understand the detailed anatomical distribution of HIV-1 infected cells over time. The amount
of cell-to-cell transfer in the model depends on the number of infected T cells I and the proportion of susceptible cells
S/N at any given time. Since N , the total density of CD4+ cells, is not held constant, but in fact declines over time,
cell-to-cell spread becomes increasingly effective as HIV-1 progresses.
The model does not explicitly distinguish antigen-presenting cell to T cell (APC/T) from T cell to T cell (T/T) trans-
mission. APC/T transmission may potentially be most important very early in establishing infection [38], a process
which is not examined in detail in this model. These two types of transmission are in fact both likely to occur most
frequently and efficiently in the microenvironment of an APC/T cluster, where APC/T interactions lead to T cell acti-
vation, and hence favour also T/T interaction. Furthermore, there are very few quantitative estimates of the parameters
of APC/T interaction in vivo. The incorporation of an additional cell type is therefore unlikely to have a major effect
on the model behaviour, but would add significantly to model complexity and uncertainty.
The cause of T cell death in HIV-1 infection continues to be controversial, and probably includes several effects
including lysis of infected cells by effector cells such as CD8 T cells and NK cells, apoptosis/pyroptosis and bystander
death [27]. Non-immunological death of infected T cells is represented by a death rate of γI . And we use the term
κ II+0.1
N
NM
to model the death of infected T cells by the cellular immune response. κ is initially 0 and changes to
a higher value in Table 1 when the cellular immune response kicks in D (default value: 30) days after the initial
infection. The term II+0.1 captures the relationship between the strength of the immune response and the density of
infected CD4+ T cells [8]. The term N/NM captures immune exhaustion caused by HIV-1 infection. It falls from
around 1 before infection towards 0 as HIV-1 progresses (because NM is a constant and N , the total density of CD4+
T cells, gradually declines with the HIV-1 progression).
Infected cells return to a quiescent state, and become latent, at rate rI . Latent cells die and are activated (i.e. becomes
infected cells) at the same rates as quiescent cells. Infected T cells release free viruses at rate g. Free viruses die at a
rate of γV .
The abortive infection of quiescent cells is not considered in this simplified model, similarly to most previous mod-
elling studies [3, 1, 39, 40]. HIV-1 immune escape mutants [41] are not directly modelled in this paper but their effects
on degrading cellular immune response are reflected in the immune exhaustion in our model.
The numerical solutions of each of the variables are shown in Figure 1C. Figure 1B shows the combined CD4+ T cell
counts (N ) and virus load (V ), which are measured routinely in the clinic to monitor HIV-1 infection. Notably, the
qualitative behaviour of the model accurately reflects the three main phases of disease that are observed clinically.
The model reproduces an acute infection phase, where the virus replicates rapidly (reflecting the absence of any pre-
existing adaptive immunity), peaks and then returns to a low level by approximately 5 weeks. This metastable level
of virus represents the clinical “set-point”. Virus then remains stable for a prolonged period (note interruption and
change of scale in x axis), during which time T cells decline very slowly. Finally, T cell numbers start to drop faster,
and viral loads rise. The model calculation is stopped when CD4+ level reaches 200 cells/µl.
It is important to note that the term cI(S/N)θβ1 we introduced for cell-to-cell spread is mathematically different from
the classic term β2SV which captures cell-free spread. N , the total CD4+ number, is not a constant but decreases as a
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function of time. Indeed, if N in the cell-to-cell spread term is fixed, disease progression is not observed in the model
(S1 Fig). Furthermore,N cannot be expressed as a simple function of V . In Figure 1B the same value of V (free virion
density) on each side of its peak around t = 30 days corresponds to two different N (CD4+ T cell density) values. In
addition, I, the number of infected cells, is not always proportional to V, especially early in infection (S2 Fig). Thus
the term for cell-to-cell spread cI(S/N)θβ1 shows different dynamics from the classic cell-free term β2SV .
Model Evaluation
Most of the parameters of our model, and especially those determining HIV infectivity via cell-to-cell or cell-free
spreading, were obtained from experimental observations (Table 1). It was therefore important to test that the model
with this parametrization accurately fits real clinical data sets. We therefore evaluated our model against a set of
longitudinal T cell count and virus load measurements obtained from a cohort of HIV-1-infected individuals who were
recruited following clinical presentation with symptomatic acute HIV-1 infection and followed over time with serial
measurement of plasma viral RNA levels and circulating T cell counts. The subjects selected for inclusion in this study
all chose not to receive antiretroviral treatment in acute or early infection, and remained untreated until progression
towards AIDS, evidenced by a substantial decline in their circulating CD4+ T cell count (See Materials and Methods).
We use our model to theoretically reproduce the HIV-1 infection courses in the data. The values for HIV infectivity
were fixed, as derived from the literature or our own observations (Table 1). Values for five parameters (Q0, S0, NM ,
κ and D) describing the characteristics of the immune response were chosen for each patient to minimise the error
of the predicted quasi-stable level of T cell counts (Ns) and viral load (Vs), and the time of progression to AIDS
(tA). All other values remained fixed at the default values in Table 1. The predicted progression results are compared
against the actual measurements in Figure 2 and S2 Table. The predicted Vs and tA for each patient were negatively
correlated (correlation coefficient = −0.46), in agreement with the well-established relationship between these two
clinical values. Remarkably, the model can fit all patients by modifying the five immune-relevant parameters over a
narrow range. Furthermore, the parameter values which gave the best results for the patients (see S1 Table) are all very
close to those in Table 1, which were derived independently from experimental measurements.
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Figure 2: Model prediction for a cohort of treatment-naive HIV-1 patients.(A) Clinical data (circle and arrow) for
all patients under study comparing against model prediction (diamond) for the time to AIDS (tA), the quasi-steady
density of CD4+ T cells (Ns) and the quasi-steady density of free virions (Vs). An arrow represents that tA is greater
than a particular value (represented by the connected circle) for a patient as his / her CD4+ count did not reached
AIDS level (200 cells/µl) in the data.(B) Prediction (curve) of HIV progression course (N and log10V ) for four
typical patients, where clinical data are shown as dots.Full prediction results are shown in S1 Table and S2 Table.
The importance of cell-to-cell spread and cellular activation
Having confirmed that the model gives realistic estimations and predictions of real clinical data, we investigated the
behaviour of the model in more detail. The role of the two spreading routes was further examined by systematic
variation of the cell-to-cell infection rate, β1, and the cell-free infection rate, β2. The predicted outcome of infection
are shown in Figure 3. When either route is abolished, infection is blocked completely; T cell level returns to normal
7
and virus is cleared after the cellular immune response kicks in. If cell-to-cell spread is removed from the model
(β1 = 0) even a doubling in cell-free infection rate does not result in infection progression. In contrast, a doubling
of cell-to-cell infection rate increases the set-point of viral load, and greatly speeds up the progression of infection
even in the absence of cell-free infectivity. Thus the model suggests cell-to-cell spread may be an important force in
allowing virus to establish infection in lymphoid tissue [38].
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Figure 3: Two modes of HIV-1 infection. The density of CD4+ T cells as a function of time for different values of
cell-to-cell infection rate β1 and cell-free infection rate β2: (1) both use their default value, (2) β1 uses its default value
and β2 = 0, (3) β1 = 0 and β2 uses its default value, (4) β1 is twice its default value and β2 = 0, (5) β1 = 0 and β2 is
twice its default value.
In the context of the model, the transition from phase 1 (acute) to phase 2 (stable chronic) is driven by a balance
between several processes, including viral spreading through two parallel modes, and the cellular immune response,
i.e. killing of infected cells as the cytotoxic CD8+ T cell response becomes active. Paradoxically, in the stable chronic
phase, the activation of T cells, which is the hallmark of adaptive immunity and is aimed at protecting the host, in fact
contributes to the persistence of HIV-1. The role of CD4+ T cell activation is explored in Figure 4A. In this model, the
rate of T cell activation a(NM/N) increases as the number (N ) of T cells falls, which can be considered to represent
a type of homeostatic regulation reinforcing immunological activity relevant to the progressive damage of the immune
system and its consequences. In the absence of this feedback (i.e. when activation rate is fixed), HIV infection would
not progress to AIDS after the onset of the cellular immune response. In contrast, if the activation rate is doubled,
then infection progresses significantly faster to AIDS. These results confirm and extend the findings of DeBoer and
Perelson [29], which suggested an increasing rate of cellular activation was important in establishment of chronic
infection and progression to AIDS. The results are also consistent with evidence that non-pathogenic SIV infection
in the natural host species results in viral replication in the absence of chronic immune activation and no AIDS [42].
Figure 4B depicts the number of CD4+ T cells newly infected via either cell-to-cell spread or cell-free spread as the
infection progresses. The model predicts that cell-to-cell transfer becomes increasingly dominant as the total number
of CD4+ T cells falls , the proportion of susceptible cells rises (Figure 4B inset left y axis) and the strength of immune
response falls (because of immune exhaustion, see Figure 4B inset right y axis).
Treatment evaluation
Modelling can help evaluate the long term effects of different treatments on HIV-1 progression. Once the start time,
duration, and effectiveness against two modes of HIV-1 spread are known for a treatment, its effects on HIV-1 pro-
gression can be evaluated by the model.
To validate the model’s ability to evaluate HIV-1 treatments, we use it to theoretically reproduce the results of the Short
Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial [28]. The SPARTAC trial aims to evaluate how the
short-course antiretroviral therapy (ART) delays HIV progression. The patients (366 in total) who participated in the
trial were randomly assigned to three groups: standard care, 12-week ART treatment, and 48-week ART treatment.
For these three groups of patients, the primary end point tp (defined as when CD4+ count ≤ 350 cells/µl or the
start of long-term ART) on average reached 157 weeks (standard care), 184 weeks (12-week ART), and 222 weeks
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Figure 4: Progressive CD4+ T cell activation drives progression to AIDS and increased cell-to-cell infection.(A)
Progression of HIV-1 infection for different cell activation rates, including (1) normal activation (aNM/N in equa-
tion (1)), (2) fixed activation (aNM/N0, where N0 is the initial density of CD4+ T cells), and (3) doubled activation
( 2 × aNM/N when t > D).(B) Numbers of newly infected cells in a day via cell-to-cell spreading and cell-free
spreading, respectively. The inset shows the ratio of susceptible cells to all cells (S/N , left y axis) and the strength of
immune response (κ II+0.1
N
NM
, right y axis) as a function of time, respectively.
(48-week ART) after randomisation. Randomisation is the time when the trial starts .
We first estimate the trial time points (randomisation, start of the treatments, and primary end points tp) in terms of
days after the initial infection (See Materials and Methods). We then use the average CD4+ count and virus load of
all patients at randomisation, and the primary end point of the patients in standard care group to fit the five immune-
relevant model parameters (Q0, S0, NM , κ and D). These fitted parameters represent an average patient in the trial.
We then evaluated the effects of 12 and 48 week therapy using the model. We assumed that the therapy was 100%
effective against cell-free transmission, but we evaluated the model for both 100% and 50% efficiency against cell-to-
cell transmission, since cell-to-cell transmission has been reported as being more resistant to some forms of therapy
[43, 44]. Both modalities reproduced the observed effects of therapy well, and the model results were robust to changes
in the efficiency (Table 2). The model therefore not only fits known data sets (standard care group) but also accurately
predicts the effects of new treatment regimes on two independent patient groups (12-week and 48-week).
Table 2: Model prediction of the SPARTAC trial
Patient groups: Standard-care 12-week-treatment 48-week-treatment
Nr (cells/µl) ∗ Data: 559
Model: 560
Vr (virons/µl) ∗ Data: 17 (log10Vr = 1.2)
Model: 12 (log10Vr = 1.1)
tp (days) Data: 1,197 1,386 1,652
Model: 1,197 1,392 | 1,394 1,654 | 1,656
Nr and Vr are the density of CD4+ T cells and free virions at the randomisation (when patients groups are randomly divided and
the trial starts). tp is the time between the initial infection and the primary end point (when density of CD4+ T cells decreases to
350 cells/µl or the start of long-term ART [28]). The tp estimated from the model is the time when CD4+ T cells decreases to
350 cells/µl. The Materials and Methods section describes how tp is inferred from the data [28] in terms of days after infection.
The model parameters calibrated from the trial data (by fitting the average Nr , Vr for all patients and tp for the standard care
group) are Q0 = 566 cells/µl, S0 = 13 cells/µl, NM = 638 cells/µl, κ = 1.292165 /day and D = 28 days. The trial
treatment is assumed to be 100% effective against cell-free HIV-1 spread. We estimate the tp for 12-week and 48-week treatment
groups if the treatment is 50% (value in bold font) or 100% (value in normal font) effective against cell-to-cell spread of HIV-1.
*For the three patient groups, the model predication uses the same Nr and Vr , which are the average of all patients in the trial.
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We therefore further explored the sensitivity of the model to perturbation as a function of treatment starting time
(Figure 5). The “treatment” lasts for 30 days, during which both cell-free and cell-to-cell infection are completely
blocked. Once “treatment” is finished, two modes of HIV-1 infection resume. Early treatment in this model (3
days after infection, i.e. post-exposure prophylaxis) leads to no decline in CD4+ T cell density, and no chronic
infection phase. The same treatment applied when T cell density reaches the levels (500 CD4+ T cells/µl and 350
CD4+ T cells/µl) at which the World Health Organization recommends ART initiation [45] is followed by a rapid
virus rebound after the treatment stops, and the disease progresses according to its normal course. Thus , as HIV-1
progresses it becomes increasingly difficult to control infection in this model.
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Figure 5: Impact of treatment starting time on HIV progression. HIV progression for a 30-day ‘perfect’ treatment
starting at three different times after the initial infection: (1) on the 3rd day when the density of all CD4+ T cells is
N = 725 cells/µl, (2) when N = 500 cells/µl; (3) when N = 350 cells/µl. The ‘prefect’ treatment here means
both cell-to-cell infection and the cell-free infection are completely blocked (i.e. β1 = 0, β2 = 0 and the virus release
rate g = 0) for 30 days.
Finally, we looked at the interactions between treatment starting time, activation rate and efficiency of therapy against
cell-to-cell spread (Figure 6). In general, increased efficiency of therapy and earlier treatment both prolonged time
to progression to AIDS. However, the effects of altered activation depend in a complex way on the context of the
intervention. Blocking activation early is beneficial, since it will reduce the number of susceptible cells HIV-1 can
infect; while blocking activation late, when the latent HIV-1 reservoir has been established, will prevent latent HIV-1
from being activated and eradicated. Increasing cellular activation, which has been proposed as a means of flushing
out the latent reservoir [46], can be effective in increasing time to AIDS when given in the context of efficient anti-viral
therapy, but can shorten the time if concomitant anti-viral therapy is incomplete. This is because increasing cellular
activation increases both the number of susceptible cells (activated from quiescent cells) and the number of infected
cells (activated from latent cells) at the same time. Thus if it is used together with an effective anti-viral therapy, the
latent HIV-1 reservoir will be flushed out and killed by the antiviral drugs. But if the concomitant anti-viral therapy is
not efficient enough to clear the increased number of infected cells, the spread of HIV-1 will speed up.
Discussion
The aim of this study was to develop a model that reduces the enormous biological complexity of the course of HIV-
1 infection to a few well-defined equations but nevertheless retains the main dynamic features of the disease. In
particular, the model was required to predict the evolution of a long lived metastable state of low level viral infection,
which ultimately breaks down to uncontrolled viral growth and a precipitous fall in CD4+ T cells, two hallmarks
of AIDS. The model incorporates both an immune response, which is believed to be a major factor limiting viral
expansion by killing of infected cells, and the formation of long lived latently infected cells, which are believed to
play an important role in limiting the long-term effects of antiviral therapy. The key distinguishing features of the
model are that it incorporates explicitly cell-to-cell spread of virus as well as classical spread via cell-free virus. The
motivation of building such a model was to investigate the role of these two modes of spread in determining the
outcome of infection, and thus complement the limited in vivo experimental and clinical data available addressing this
10
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Figure 6: Prediction of the time to AIDS, tA, for different treatment schemes.We consider 30-day treatments
starting (A) on the 3rd day and (B) when N = 500 cells/µl, respectively. All treatments block cell-free infection
completely (β2 = 0 and g = 0). The treatments also affect cell-to-cell infection (x axis) and / or manipulate the CD4+
T cell activation process (y axis, see Figure 4A). The black squares represent treatments that reduced the density of
infected cells, latent cells and free virions all below 10−12 per µl.
question.
A fundamental prediction of the model is that, given the known experimentally derived parameters of cell-to-cell and
cell-free spreading, the two modes of spread complement each other and both make important contributions to disease
progression. In addition, it is clear that there is a close relationship between the proportion of activated T cells, cell-
to-cell spread and disease progression. Specifically, cell-to-cell spreading is strong when the percentage of activated,
and therefore susceptible cells is high in the population, since an infected cell is then more likely to encounter an
effective target (a susceptible cell) to infect. When the percentage of susceptible cells is low, infected cells will mostly
encounter quiescent/resting cells that will provide ineffective targets. These conditions may occur both early and
late in HIV-1 infection. The site of infection itself (for example the vaginal mucosa) may contain large proportion of
activated T cells some of which may be interacting with APC, particularly if there is a concomitant sexually transmitted
infection. The well-documented association between HIV-1 infection and other mucosal infections may therefore
reflect the key importance of a high concentration of APC and activated T cells in early transmission of virus [47].
There is also convincing evidence that gut associated lymphoid tissue is a major site of viral replication early on in
disease [48, 49]. This tissue is characterized by an unusually large proportion of T cells capable of supporting HIV-1
replication, presumed to result from chronic exposure to the gut microbiome. Since cell-to-cell spread is much more
efficient, and under these conditions the number of activated target cells are not limiting, our model predicts that gut
lymphoid tissue would provide an ideal microenvironment for rapid propagation of HIV-1, at least until the majority
of target cells are infected or die. Further development of the basic model, to allow heterogeneity associated with
different anatomical compartments would allow this prediction to be tested directly.
The model also predicts a dominant role for cell-to-cell spread in the late phase of HIV-1. As in the scenario early in
infection in the gut lymphoid tissue, our model predicts that late stage disease will be associated with a large number
of infected cells, combined with a large proportion of activated target cells. A high number of infected cells is a simple
corollary of the very high levels of free virus late in infection in the absence of treatment. There is also substantial
experimental evidence for increased immune activation in the late phases of HIV-1 [26], and indeed this has been
proposed as an important contribution to pathogenesis. Thus cell-to-cell spread is likely to become the dominant
mode of transmission in the late stages of HIV-1. This may be important in light of recent data showing that the
different components of current HAART display variable efficacy against cell-to-cell spread [43, 44].
Interestingly, the hybrid spreading mechanism employed by HIV-1 is reminiscent of those of some computer worms
such as Red Code II and Cornficker [20, 21], which allocate their resources between probing for susceptible target
computers in local area networks and globally across the internet. Similarly to HIV-1, local interactions have a high
chance of success but access only a limited number of targets while global spread targets a much larger number of
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targets with a much lower probability of success. Modelling studies have shown that this hybrid spreading is required
to explain the large outbreak of such worms on the Internet [25]. It is tempting to speculate that hybrid spreading may
contribute to the pathogenicity and dynamics of infection of other viruses that employ parrallel spreading mechanisms,
for example Hepatitis C virus [19].
The current model incorporates some simplifying assumptions. Nevertheless, the model does provide some insights
into the effectiveness of therapy at different stages of disease. Specifically, the model strongly supports the hypothesis
that interfering with viral infection early in HIV-1 progression is likely to have a major impact on the subsequent
progress of the disease. Interfering with viral transmission is predicted by our model to be much more effective
early in HIV-1 infection. The clinical decision about when to start therapy remains a matter of debate. Current
WHO guidelines suggest commencing treatment at CD4+ T cell density of > 350cells/µl and < 500cells/µl [45].
However, studies exploring much earlier commencements of treatment, have claimed increased efficacy [50, 28]. For
example, the recent “Short Pulse Anti-Retroviral Therapy at Seroconversion” (SPARTAC) trial, demonstrated a long
term clinical benefit of a limited period of ART soon after seroconversion [28]. Our model accurately predicted the
results of the SPARTAC trial providing further support for the model’s generality and robustness.
Anti-viral therapies that specifically target cell-to-cell spread are not currently available, but are clearly important
therapeutic goals [44]. A number of previous studies have proposed combining antiviral therapies with therapies that
either limit CD4+ T cell activation (thus reducing the number of target susceptible cells) or increased T cell activation,
thus flushing out reisdual latent cells. These approaches have not given clear cut clinical benefits [51, 52]. Indeed
our model suggests that the outcome of such manipulation of cellular activation will be critically dependent on the
time at which it is administered, and the efficiency of concomitant antiviral therapy. Targeted suppression of CD4+
T cell activation, in combination with antiviral therapies may nevertheless offer a useful approach, if used early on in
infection.
Mathematical models provide an important tool for understanding and predicting the course of natural HIV-1 infection
that complements clinical studies. The most appropriate therapeutic regimens for HIV therapy continue to remain the
subject of disagreement and debate. In addition, many new therapeutic modalities aimed at achieving viral eradication,
such as the HDAC inhibitors [46], or therapeutic vaccination [53] are being proposed. However, testing new treatment
regimens is a costly and time consuming task, and the logistic challenges and expense of running clinical trials to
evaluate and compare treatments remain a major bottleneck to translational advances in HIV therapy. Mathematical
models have proved of value in the past, but have suffered from omitting important biological processes, thus com-
promising their ability to accurately recapitulate clinical observations. Our model explicitly incorporates cell-to-cell
transmission, and changing rates of cellular activation, two processes that are known to be a key feature of HIV in-
fection. With increased sophistication, and hence ability to accurately model the known biological drivers of disease
progression, mathematical models can become increasingly important in preclinical testing of modified or novel HIV
therapies. The model developed here provides specific predictions which emerge from the close links between CD4+
T cell activation and cell-to-cell spread, and their combined contribution to both early and late phases of HIV-1. These
predictions emphasize the potential benefits of early or prophylactic treatment with antiretroviral therapies, and sug-
gest that drugs with the ability to effectively block cell-to-cell spread may provide significant therapeutic benefit in
long term management or eradication of HIV-1 infection.
Materials and Methods
Recruitment and follow-up of HIV-1 infected patients (London data)
Individuals acutely-infected with HIV-1 were recruited at the Mortimer Market Centre for Sexual Health and HIV
Research (London, UK). Subjects were mostly male Caucasians who presented with symptoms of acute retroviral
illness. Patient viral loads and CD4+ T cell counts were measured longitudinally at serial time-points following
infection using standard clinical tests. All subjects were offered anti-retroviral treatment at diagnosis. The subjects
selected for inclusion in the study all chose not to receive anti-retroviral therapy in acute or early infection, and
remained untreated until disease progression, evidenced by a substantial decline in their circulating CD4+ T cell count
occurred.
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Ethics Statement
Patients provided written informed consent for study participation. Study approval was obtained from The National
Health Service Camden and Islington Community Local Research Ethics Committee.
Selection of patients to be included in the study (London data)
There were 39 patients in total in the data from Mortimer Market Centre for Sexual Health and HIV Research (London,
UK). For this study, we focused our analysis only on patients with more than ten data points for both HIV load and
CD4+ measurements (29 out of the 39 patients). We also excluded from the analysis a further 12 patients who showed
no overall decrease in CD4+ count, or no increase in viral load at later timepoints. The focus of the model described
above is to capture the “typical” characteristics of HIV infection, which include that CD4+ count falls in general,
and viral load increases in general as infection progresses. It is widely accepted that in some patients (for example
the so-called “elite controllers”) viral load remains low or undetectable and CD4+ count remains unchanged for long
periods. The mechanisms responsible for these phenomena are still incompletely understood. The current model does
not attempt to incorporate any such mechanism, and this group of patients was therefore not included in the study.
Further elaboration of the current model to include additional features of viral control will be informative in helping
to understand such patients. The identifiers for the remaining 17 patients are: MM1, MM4, MM8, MM9, MM12,
MM13, MM23, MM24, MM27, MM33, MM39, MM40, MM42, MM43, MM45, MM57, MM60.
Estimation of the time points of the SPARTAC trial
According to [28], the median interval between seroconversion and randomization (start of trial) was 12 weeks. The
exact average time of seroconversion for patients in the SPARTAC trial is not directly available from [28]. We assume
it is 2 weeks after initial infection, as seroconversion normally happens within a few weeks after HIV-1 infection. Then
the time of randomization (start of trial) can be estimated as 7(2 + 12) = 98 days after infection. The treatment is
estimated to start 3 days after randomization [28], i.e. 98 + 3 = 101 days after infection. And the primary end points
for patients in standard care, 12-week ART, and 48-week ART groups are respectively: 98 + 7 × 157 = 1197 days,
98 + 7× 184 = 1386 days, and 98 + 7× 222 = 1652 days after infection.
Availability and implementation
Calculation results in this paper are obtained using LeoTask [54], a parallel task running and results aggregation
framework that we have developed for computational research. The framework and an executable programme that
implements our HIV-1 model are both freely available at http://github.com/mleoking/leotaskapp.
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Supporting Information
S1 Table
Model parameters calibrated from a cohort of treatment-naive HIV-1 patients. Results are shown for all 17
patients. In the data, time is recorded relative to the first appearance of symptoms of HIV infection. As the actual
initial infection date is unknown, we assumed a constant “eclipse” phase of 20 days between initial infection and first
appearance of symptoms.
S2 Table
Model prediction of a cohort of treatment-naive HIV-1 patients. NS is the quasi-steady CD4+ T cell density and
VS is the quasi-steady density of free virions, which are average densities between the 100th and 800th days after
initial infection. tA is the time to AIDS, which is defined as the time between initial infection and when the density of
CD4+ T cells falls to 200 cells/µl.
S1 Fig
HIV-1 infection course generated by the HIV-1 model using two different cell-to-cell infection terms: 1) the
normal cell-to-cell infection term (cθβ1IS/N ) in equation (1), and 2) the cell-to-cell infection term that fixes N to be
N0 (cθβ1IS/N0 where N0 is the total number of CD4+ T cells before HIV-1 infection and it is a constant). With a
fixed N = N0 in the term, the HIV-1 model would not be able to recapitulate the AIDS phase.
S2 Fig
V/I (density of free virions divided by the density of infected CD4+ T cells) as a function of time. There are
some obvious changes in V/I during the early days of HIV-1 infection. The figure however also supports some
existing works’ [8] assumption that V and I are proportional to each other during the chronic (stable) phrase of
HIV-1 infection. Our model depicts HIV-1 infection in all its three phrases and we do not therefore assume V to be
proportional to I .
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